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Anaphylactoid reactions associated with reuse of hollow-fiber hemodi-
alyzers and ACE inhibitors. From July 18 through November 27, 1989,
12 anaphylactoid reactions (ARs) occurred in 10 patients at a hemodi-
alysis center in Virginia. One patient required hospitalization; no
patients died. ARs occurred within minutes of initiating dialysis and
were characterized by peripheral numbness and tingling, laryngeal
edema or angioedema, facial or generalized sensation of warmth, and/or
nausea or vomiting. All 12 ARs occurred with dialyzers that had been
reprocessed with an automated reprocessing system. A cohort study,
including all patients undergoing dialysis sessions on the six days when
an AR occurred, showed that the patients who experienced ARs were
significantly more likely than patients who did not to be treated with
angiotensin-converting enzyme (ACE) inhibitors (7/10 vs. 3/33; relative
risk = 7.9; 95% confidence interval = 2.5 to 25.2) and to have been
exposed to reused dialyzers rather than to new dialyzers (12/70 sessions
vs. 0/31; P = 0.016). In those sessions using a reused dialyzer, the mean
number of dialyzer uses in case-sessions was significantly higher than
for noncase-sessions (10.3 vs. 6.2; P = 0.016). After reuse of dialyzers
was discontinued at the center, no further ARs occurred, despite the
continued administration of ACE inhibitors. This is the first report of an
outbreak of ARs associated exclusively with reused dialyzers. We
hypothesize that interactions between a dialyzer that has been repeat-
edly reprocessed and reused, blood, and additional factors, such as
ACE inhibitors, increased the risk of developing ARs.
Anaphylactoid reactions (ARs) in some patients undergoing
hemodialysis with first use of a dialyzer have been associated
with different dialyzer membranes, especially Cuprophan'
membranes, and residual amounts of ethylene oxide gas used to
sterilize dialyzers [1—5]. These reactions often occur within two
to three minutes of initiating dialysis and range in severity from
mild itching to life-threatening systemic reactions characterized
by bronchospasm, hypotension, and cardiopulmonary collapse.
While 31% of U.S. chronic hemodialysis centers reported
reactions associated with new dialyzers (first-use syndrome) in
1989, severe ARs are rare [6]. In 1982, it was estimated that
there were 3.5 severe ARs per 100,000 hollow fiber dialyzers
sold; none of these reactions were associated with reused
dialyzers [7].
In the United States, reuse of disposable hemodialyzers for
the same patient is a common practice. From 1977 through
1989, the proportion of centers that reused dialyzers for the
same patient increased from 18% to 68% [61. The primary
reasons for dialyzer reuse are the cost savings of reuse and
avoidance of first-use syndrome. Reuse procedures are consid-
ered safe when standards of the Association for the Advance-
ment of Medical Instrumentation are maintained [8, 91.
Reused dialyzers have been associated with outbreaks of
infection with a variety of microorganisms and with an in-
creased incidence of pyrogenic reaction compared with first-use
dialyzers [6, 10—12]. In general, these outbreaks resulted from
inadequate reprocessing procedures. However, outbreaks of
ARs associated with reused dialyzers previously had not been
reported. In 1989, we investigated an AR outbreak in patients at
a dialysis center in Virginia.
Methods
Background
Continental Dialysis Center of Springfield-Fairfax (CD-SF) is
a privately-owned outpatient hemodialysis clinic with nine
dialysis stations. Forty-eight patients receive their hemodialysis
treatments at the center; all have chronic renal failure and
receive conventional acetate or high-flux bicarbonate hemodi-
alysis. The center operates three shifts on Mondays, Wednes-
days, and Fridays and two shifts on Tuesdays, Thursdays, and
Saturdays. Patients are usually dialyzed at the same station
utilizing the same dialysis machine. Conventional dialysis treat-
ments are performed by using Travenol SPS-450' (Travenol
Laboratories, Inc., Deerfield, Illinois, USA) dialysate delivery
systems and hollow-fiber dialyzers with cellulose acetate or
CuprophanTM membranes. High-flux dialysis treatments are
performed by using Fresenius A 2008D (Fresenius AG, Bad
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Homburg, Germany) delivery systems and polysulfone hollow-
fiber dialyzers (Hemoflow F-80; Fresenius AG).
Manual reprocessing of hemodialyzers was instituted by
CD-SF in 1986 and continued until 1988. Since 1988, dialyzers
have been reprocessed by using an automated reprocessing
system (DRS-4; Seratronics, Inc., Concord, California, USA).
New dialyzers were not reprocessed before first use.
From July through September 1989, eight patients from
CD-SF developed ARs within minutes of beginning a dialysis
treatment session. A preliminary investigation did not identify a
source. No further cases occurred until November 27, 1989,
when four patients experienced similar reactions. Two of the
four patients developed laryngeal edema, and one of these two
required hospitalization. No patients died. On November 29,
the Centers for Disease Control (CDC) was invited to assist the
Food and Drug Administration and Virginia State Department
of Health in the investigation.
Case definitions and ascertainment
An AR was defined as the occurrence of two or more of the
following signs or symptoms within 10 minutes of initiating a
hemodialysis treatment in a patient at CD-SF from January 1
and November 27, 1989: (1) generalized sensation of warmth;
(2) numbness or tingling of the fingers, toes, lips, or tongue; (3)
swelling or fullness in the mouth or throat; (4) shortness of
breath, audible wheezing, or chest tightness; (5) nausea, vom-
iting, or diarrhea; (6) angioedema or laryngeal edema; or (7)
30 mm Hg fall in systolic blood pressure from predialysis
measurement. We defined a case-patient as any patient who
experienced an AR. A case-session was any hemodialysis
treatment session in which an AR occurred.
Case finding was performed by reviewing medical records,
including dialysis treatment records, for all patients receiving
hemodialysis at CD-SF from January 1 through November 27,
1989.
The first AR during this period occurred in two patients
undergoing hemodialysis on July 18, 1989; the last reactions
occurred in four patients undergoing hemodialysis on Novem-
ber 27, 1989. Therefore, we defined the epidemic period as July
I through November 27, 1989, and the preepidemic period as
January 1 through June 30, 1989.
Epide,niologic studies
Cumulative incidence rates of AR were compared for the
epidemic and preepidemic period. To identify risk factors for
ARs, we performed a cohort study of all patients receiving
dialysis treatments on the six days when reactions occurred.
Patient data examined included: age, race, sex; cause of end-
stage renal disease; total duration on hemodialysis; history of
drug allergy; medications administered; and signs and symp-
toms of ARs. Treatment data examined included day of week
and treatment shift; onset and duration of treatment session;
type of dialysis machine, dialysate, nd dialyzer; type of
arterial-venous fistula needle; and receipt of intradialytic med-
ications. For all reused dialyzers, we also examined the reuse
number, the date and time of reprocessing, reprocessing sta-
tion, results of the pressure leak test, ultrafiltration rate, and
total blood volume.
Water treatment system (WTS)
The water used by the CD-SF is chlorinated surface water
supplied by the municipal water system. Hot and cold munici-
pal water are mixed to 25.5°C and passed sequentially through
a sand filter, water softener, and two carbon filters alternating
with two 5 jsm filters. The water is then filtered through two
reverse osmosis (RO) units and continuously circulated to nine
dialysis stations and then to drain. The RO units and water
distribution system undergo disinfection each month with 4.5%
formaldehyde; the last disinfection before the investigation was
November 11, 1989.
Dialyzer reprocessing and retise
Duringthe epidemic and pre-epidemic periods, the method of
dialyzer reprocessing was unchanged. The dialyzer blood and
dialysate compartments were rinsed manually with RO water
for three to five minutes before reprocessing with an automated
system (DRS4, Seratronics). Following the flush cycle, the
dialyzer was filled with a 10% hydrogen peroxide solution,
rinsed with RO water, tested for total cell volume (TCV) and
membrane integrity. After completion of the test cycle, the
dialyzer was filled with a 3.3% concentration of Renalin
(Minntech Corp., Minneapolis, Minnesota, USA), a peracetic
acid/hydrogen peroxide-based solution blended from a 33%
Renalin feed solution, and capped. A label, which includes
patient information, the results of dialyzer testing, and the
dialyzer reuse number, was affixed to the dialyzer, and the
dialyzer was stored at room temperature until the next use. The
dialyzer could be used within 24 hours to one week after
reprocessing. Dialyzers were discarded if they failed the TCV
or membrane integrity tests or after 20 uses. Routine mainte-
nance and calibration of the reprocessing machine were per-
formed monthly.
Before patients received dialysis, the presence of Renalin in
the dialyzer was confirmed by using Renalin Indicator test
strips (Minntech Corp.). After the patient information, test
results, and use number on the dialyzer label were confirmed,
the dialysate lines were attached to their appropriate ports and
the dialysate compartment was filled with dialysate with the
arterial end of the dialyzer up. The arterial and venous lines
were attached to the dialyzer and 500 ml of saline was rinsed
through the dialyzer blood compartment and discarded. The
arterial and venous lines then were connected together, the
blood pump set to 200 ml with 100 mm Hg negative pressure,
and saline was recirculated through the dialyzer for at least 10
minutes, until the initiation of dialysis. Just before the initiation
of dialysis, the blood circuit was checked for residual germicide
by using Renalin Residual test strips (Minntech Corp.). If
germicide was detected, 300 ml of saline was discarded from
the blood line and the blood circuit was checked again for
residual germicide until none was detected. If germicide was
not detected, an additional 200 ml of saline was discarded from
the blood line and dialysis was initiated.
Laboratory investigation
On December 4, 1989, Renalin concentrate was reconstituted
by CD-SF reprocessing technicians and 50 ml samples of the
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reconstituted solution were collected. The Renalin concentra-
tion of the reconstituted solution and from dialyzers repro-
cessed at CD-SF on November 25 and 27, 1989, was determined
at CDC by peracetic acid and hydrogen peroxide titration [13].
Bacteriologic assays of the fluid of the reprocessed dialyzers
were done by the membrane-filter technique [14]. Specimens
from the blood and dialysate compartments were filtered
through 0.45 sm filters, and the filter membranes were plated
directly on trypticase-soy agar plates. The plates were incu-
bated at 37°C, and colony counts were done at 48 hours.
Statistical analysis
Categorical variables were compared by using chi square or
Fisher exact test; relative risk (RR) and 95% confidence inter-
vals (95% CI) were calculated. Continuous variables were
compared by Kruskal-Wallis one-way analysis of variance by
ranks [15]. Epi-Info version 5 (CDC, Atlanta, Georgia, USA)
was used for data entry and statistical analysis.
Results
Case-finding and ascertainment
From January 1 through November 27, 1989, 12 cases of AR
occurred in ten patients; one patient had three ARs (Fig. 1).
ARs occurred on all treatment days except Friday and were not
temporally associated with the monthly disinfection of the RO
units or WTS. From one to four ARs occurred on each of the six
days when reactions were diagnosed, and from one to two ARs
occurred per treatment shift. The rate of AR was significantly
higher during the epidemic period than during the pre-epidemic
period (12/2031 dialysis treatments vs. 0/2641; P < 0.001).
All 12 ARs occurred during dialysis sessions involving a
reused dialyzer (Table 1). During 1989, no reactions occurred
with first-use dialyzers. The 12 ARs occurred within several
seconds to 8 minutes (median I mm) of the initiation of dialysis
and were characterized by a sensation of warmth (75%), full-
ness in the mouth or throat (58%), tingling paresthesias (50%),
nausea/vomiting (33%), tightness in the chest (33%), and short-
ness of breath (8%). During 11 of the ARs, dialysis was
discontinued; in the other, the patient had transient symptoms
which resolved without interrupting dialysis. During nine of the
11 ARs for which dialysis was interrupted, symptoms resolved
within one to five minutes of discontinuing dialysis. In the
remaining two, patients developed angioedema of the lips and
tongue; one of these patients required hospitalization. No
patient experienced respiratory arrest or died. The ARs did not
recur when dialysis was resumed using new, unused dialyzers.
Epidemiologic studies
Forty-four patients received 101 dialysis treatments on the
six days of the study period when patients experienced ARs.
Case-patients were significantly younger than noncase-patients
(46.4 years vs. 59.8 years; P = 0.02). In addition, case-patients
were significantly more likely than noncase-patients to be
receiving angiotensin-converting-enzyme (ACE) inhibitors
(7/10 vs. 3/34; RR = 7.9; 95% CI = 2.5 to 25.2). Of the seven
case-patients receiving ACE inhibitors, five (71%) were receiv-
ing enalapril and two (29%) were receiving captopril for a
median of three months before the ARs occurred (range: 2
weeks to 6 months). No significant differences existed in the
other patient characteristics examined, including etiology of
underlying renal disease, hematocrit, sex, history of drug
allergy, duration of hemodialysis, and receipt of any other
medication.
When we compared treatment session characteristics of case-
and noncase-patients, no significant differences existed in rate
of ARs by weekday or shift of the dialysis treatment session, or
by the type of dialysate. The rate of ARs was higher in sessions
using a high-flux polysulfone hollow-fiber dialyzer compared
with conventional dialyzer types (that is, cellulose acetate or
Cuprophan'), although this difference did not reach statistical
significance (high-flux vs. conventional dialyzer: 6/30 vs. 6/71;
RR = 2.4; 95% CI = 0.8 to 6.8). Restricting the analysis to the
24 dialysis treatment sessions performed on patients who were
taking ACE inhibitors did not appreciably change the risk of
developing ARs associated with high-flux compared with con-
ventional dialyzers (6/12 vs. 3/12; RR = 2.0; 95% CI = 0.6 to
6.2).
Next, we examined staff initiating dialysis sessions, and
found that the rate of ARs was higher for dialysis sessions
initiated by one of the dialysis technicians/nurses compared
with sessions initiated by the other 11 technicians/nurses com-
bined (technician/nurse #1 vs. all others: 2/4 vs. 10/97; RR =
4.8; 95% CI = 1.6 to 15.2). However, ARs occurred during
treatment sessions initiated by eight different dialysis techni-
cians/nurses, and no technician/nurse was associated with more
than two ARs.
There was also a tendency for patients dialyzed at station #4
to have higher rates of AR compared to the other eight stations
combined (5/14 vs. 7/87;RR = 4.4;95% CI = 1.6 to 12.1). Three
different case-patients experienced ARs after the initiation of
dialysis at station #4 (range: 1 to 3 ARs/patient); two of these
patients were receiving conventional dialysis, and the third
case-patient was receiving high-flux dialysis on a different
dialysis machine. Patients experienced ARs at four of nine
dialysis stations. In addition, 15-gauge arterial-venous (AV)
fistula needles brand A was associated with a higher case rate of
ARs compared to the other brand of AV fistula needles used at
the center (9/44 vs. 3/57; RR = 3.9; 95% CI = 1.1 to 13.5).
When we examined the relationship between cases of ARs
and medications administered before a treatment session, we
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Fig. 1. Distribution of cases by day of dialysis session, CD-SF,
January 1, 1989—November 27, 1989,
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Table 1. Demographic characteristics of case-patients, Center A, January I—November 27, 1989
2 Hypertensive
3 Diabetic
4 Diabetic
5 Diabetic
6 Polycystic
7 Hypertensive
8 Diabetic
9 Hypertensive,
s/p bilateral
nephrectomy
10 Glomerulonephritis
Date
AR
07/18/89
08/08/89
08/10/89
+ 07/18/89
+ 08/09/87
+ 08/09/89
— 08/10/89
+ 09/23/89
— 11/27/89
+ 11/27/89
+ 11/27/90
— 11/27/89
Shift Dialyzer
number type
found no significant difference in the receipt of corticosteroids
or dosage of heparin administered before case- and noncase
sessions. However, the rate of AR was significantly greater in
sessions with a reused dialyzer than with sessions with a
first-use dialyzer (12/70 vs. 0/31; RR undefined; P = 0.016).
Also, the mean number of hemodialyzer reuses in case-sessions
was significantly higher than in noncase-sessions that used
reprocessed dialyzers (10.3 vs. 6.2; P = 0.016). No significant
difference existed in the rate of AR analyzed by the day of
dialyzer reprocessing or the reprocessing station used in the
automated reprocessing system. Because all ARs were associ-
ated with reused dialyzers, it was not possible to assess the
contribution of receipt of ACE inhibitors, dialysis technician,
station, and type of AV-fistula needle to the risk of developing
ARs independent of dialyzer reuse.
Procedure review and laboratory investigation
All 12 dialyzers associated with ARs had passed the auto-
mated tests for TCV and membrane integrity, and tested
negative for the presence of residual germicide before reuse.
One of 12 dialyzers associated with ARs tested weakly positive
for residual Renalin following 10 minutes of saline recirculation,
but tested negative after an additional 500 ml of saline was
discarded from the blood line. On December 4, 1989, we
observed technicians preparing Renalin stock solution for use
with the automated reprocessing system. Full-strength Renalin
from one of the lots used during the outbreak was manually
diluted 1:3 with RO water in a 19-liter container to achieve a
33% dilution. The container then was shaken vigorously for one
minute. The Renalin concentration of the resulting solution was
tested to be 29.2%.
Dialysis with reused dialyzers was stopped during the third
treatment shift on November 27. 1989. Twelve dialyzers that
had been reprocessed with Renalin on November 25, 1989 and
one dialyzer similarly reprocessed on the morning of November
27, 1989 were assayed for Renalin concentration and bacterial
growth. Renalin concentration ranged from 2.3% to 3.1% (me-
dian 2.7%) in the dialyzer blood compartments and from 2.3%
to 3.4% (median 2.8%) in the dialysate compartments. No
bacteria were isolated from the blood or dialysate compart-
ments of the 13 dialyzers.
Discussion
In this investigation, cases of ARs were strongly associated
with hemodialysis with a reused dialyzer. All 12 cases of ARs
were associated with reused dialyzers, and no further cases
occurred after reuse of dialyzers was discontinued on Novem-
ber 27, 1989. Clusters of ARs occurring exclusively with reused
dialyzers previously have not been described. Hitherto, ad-
verse events associated with reused dialyzers have been almost
exclusively due to inadequate reprocessing procedures such as
the use of incorrect germicide concentrations and water that did
not meet AAMI standards [10—12]. However, in this investiga-
tion, epidemiologic and laboratory studies did not identify
specific deficiencies in dialyzer reprocessing or preparation for
reuse associated with ARs.
Although the type of dialyzer membrane was not a risk factor
for developing ARs, the mean number of dialyzer uses in
case-sessions was significantly higher than for noncase-sessions
during which a reused dialyzer was used. This finding suggests
that factor(s) associated with the repeated reprocessing and
reuse of hemodialyzers may increase the risk of developing an
AR within minutes of the initiation of dialysis with a reused
dialyzer. Because standardized procedures were utilized for all
reused dialyzers, it was not possible to further assess the role of
Case- Underlying renal ACE!
patient disease use
I Polycystic +
Dialyzer
use Time to Signs/symptoms
number AR mm of AR
1 PS 4 1 a,g
I PS 3 1 a,c,e
I PS 2 1 a,c,d,e,g
I PS 12 <1 a,b,d
I PS 15 <1 a,g
3 CA 7 5 a,e
2 CA 19 1 b,c
I CA 16 8 a,b,g
I CF 9 <1 a,c,e,f,h
2 PS 9 1 a,b,c
3 CA 12 1 c,d,e,f
3 CA 16 1 a,b,d
Abbreviations are: ACEI, angiotensin-converting enzyme inhibitor; AR, anaphylactoid reaction; key to dialyzer type: PS, polysulfone; CA,
cellulose acetate; CF, Cuprophane.
a generalized sensation of warmth
b numbness/tingling fingers, toes, lips, or tongue
C fullness in the mouth or throat
d shortness of breath, bronchospasm, chest tightness
C nausealvomiting
angioedema, laryngeal edema
g fall in systolic blood pressure  30 mm Hg
h hospitalized
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reprocessing practices on the risk of developing ARs at this
center.
Recently, severe anaphylactoid reactions have been ob-
served during hemodialysis with first-use polyacrylonitrile high-
flux membranes (AN69) in patients receiving ACE inhibitors
[16—21]. In several the reports, ARs occurred with AN69
membranes during first use and reuse of dialyzers [18, 21]. The
authors hypothesized that these reactions might be secondary
to modification of bradykinin metabolism, involving activation
of Factor XII (Hageman factor) by the negatively charged
polyacrylonitrile membrane and inhibition of bradykinin catab-
olism by ACE inhibitors [17, 211. We also found an association
between ARs and patients treated with ACE inhibitors; seven
of 10 case-patients were receiving an ACE inhibitor at the time
of the AR. However, in this investigation, no significant differ-
ence existed in the rate of AR among patients receiving hemo-
dialysis with high-flux (polysulfone) or conventional (cellulose
acetate or cuprophane) dialyzer membranes, and unlike the
previous reports, all ARs were associated with reused dialyz-
ers.
Angioedema is reported to occur in 0.1% to 0.2% of patients
receiving ACE inhibitors and usually occurs within the first
month of therapy [221. In this investigation, seven of the 10
case-patients had been receiving ACE inhibitors for a median of
three months before the ARs occurred and continued to receive
this medication after dialyzer reuse was stopped without expe-
riencing further ARs. These observations suggest that ACE
inhibitors alone were not the source of the ARs. However, ARs
may have resulted from an interaction of ACE inhibitors with
dialyzer membrane surfaces that may have been modified by
repeated reuse and reprocessing.
Patient and treatment session characteristics also may have
contributed to the occurrence of ARs. Comparison of patient
characteristics revealed that case-patients were significantly
younger than noncase-patients. The explanation for this is
unclear. Previous studies have shown that age is not a risk
factor for immediate hypersensitivity reactions except through
duration of exposure to some immunogen [231. Although case-
and noncase-patients had been undergoing hemodialysis at
various facilities for a similar duration (809 days vs. 877 days),
case-patients had been dialyzed at CD-SF for a mean of over
300 days more than noncase-patients; however, this difference
was not statistically significant.
Of the treatment session characteristics examined, the use of
a brand of 15-gauge AV fistula needles and having dialysis
initiated by one of the 11 dialysis technicians/nurses were
associated with a significantly higher rate of ARs. The 15-gauge
needles had been sterilized with ethylene oxide by the manu-
facturer, and allergic reactions due to residual ethylene oxide in
first-use dialyzers have been described [3, 4]. These 15-gauge
needles were used exclusively with both new and reused
polysulfone dialyzers and large TCV cellulose acetate dialyzers
used for high-efficiency dialysis, whether the dialyzer was new
or reused. If the mechanism of ARs at this center was exposure
to residual ethylene oxide in the AV fistula needles or other
dialysis components, such as new dialyzers or blood lines,
cases should have occurred during sessions using both new and
reused dialyzers. However, no cases occurred in nine treatment
sessions using a first-use dialyzer with 15-gauge AV fistula
needles on the six days when cases of ARs occurred. In
addition, rinsing new dialyzers with saline before first-use to
remove residual ethylene oxide and other impurities has been
reported to decrease the rate of first-use allergic reactions [3].
After August 10, 1989, AV listula needles were rinsed with 15
ml of sterile normal saline before insertion to remove residual
ethylene oxide, if present. Five additional cases of ARs oc-
curred after this procedure modification.
The pathophysiologic characteristics of the ARs associated
with reused dialyzers appear identical to those described for
allergic reactions associated with first-use syndrome. The spec-
trum of ARs occurring with new dialyzers share the common
pathophysiologic features of vasodilation, increased capillary
permeability, and smooth muscle constriction. These reactions
appear to be related to release of chemical mediators—includ-
ing histamine, leukotrienes, prostaglandins, platelet-activating
factor, and kallikrein—by tissue mast cells and/or basophils,
The biologic activity of these substances results in the cutane-
ous, cardiovascular, respiratory, and gastrointestinal effects of
ARs [24, 25].
Acute allergic reactions associated with first-use dialyzers
have been described frequently and have been related to a
variety of dialyzer contaminants, including residual particulate
material and ethylene oxide. Ethylene oxide-specific immuno-
globulin E and IgG have been demonstrated in the serum of
some patients experiencing ARs immediately after the start of
hemodialysis [3, 4]. However, the actual antigenic determinant
in the sterilizing gas has not been systematically studied. In
addition, first-use syndrome has been correlated with the ability
of different dialyzer membranes to activate complement, and
Cuprophane dialyzers are the membrane-type most likely to
cause complement activation both in vitro and during dialysis
[26-30].
Following this investigation, CDC conducted a questionnaire
survey of Health Care Financing Administration-licensed
chronic hemodialysis centers to determine the extent of ARs
associated with reused dialyzers [31]. From January 1 through
December 31, 1990, 32 (3%) of 1290 centers responding re-
ported two or more patients experiencing ARs within 10 min-
utes of initiating a hemodialysis treatment with a reused hemo-
dialyzer. Analysis of treatment characteristics and reprocessing
practices of centers reusing dialyzers indicated that ARs were
not associated with the type of disinfectant product, the repro-
cessing method (manual or automated), or type of dialysate.
The etiology of the ARs in the patients at these 32 centers
appeared to be multifactorial. The risk of ARs was associated
with use of a specific heparin product and with washing the
dialyzer blood compartment with either bleach or hydrogen
peroxide [31]. However, the survey did not assess patient
treatment characteristics, such as medication usage. Of note, of
the 762 centers that reported reusing dialyzers, most [730
(96%)] reported no ARs associated with reused dialyzers.
Further studies are needed to determine the interactions be-
tween dialyzer membranes, reprocessing practices, blood, and
additional factors, such as ACE inhibitors, which result in ARs
associated with reused hemodialyzers.
In conclusion, outbreaks of ARs among patients using reused
dialyzers are newly reported and potentially serious complica-
tions of hemodialysis. While previous studies have reported
that reused dialyzers are more biocompatible than new ones,
Pegues et a!: Anaphylactoid reactions with reused dialyzers 1237
this investigation suggests that some reused dialyzers may also
pose a risk of developing ARs to hemodialysis patients [32, 33].
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